Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer

By afschroeder • June 13, 2026

Wander SA, Weipert CM, Cabel L, Liao J, Zhang N, Safonov A, Bardia A, Razavi P. Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer. NPJ Breast Cancer. 2026 Jun 12. doi: 10.1038/s41523-026-00986-1. Epub ahead of print. PMID: 42286014.

Tags: Hematology/Oncology, Publications

Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer

Mouabbi JA, Lipsyc-Sharf MD, Yan F. Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):1-16.[...]

Interpreting MRD results and integrating assays into practice

Lipsyc-Sharf MD. Interpreting MRD results and integrating assays into practice. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):7-11. PMID: 42283708.

Practical approach to MRD testing in breast cancer: Q&A

Mouabbi JA, Lipsyc-Sharf MD, Yan F. Practical approach to MRD testing in breast cancer: Q&A. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):11-15. PMID: 42283709.